* 香港富豪李嘉诚家族旗下从事葡萄园出租与癌症疫苗研发的长江生命科技0775.HK周五早盘复牌后开盘飙升37.5%，随后涨幅扩大至41.7%，创2023年11月7日以来新高。
* 该公司此前公告称，针对滋养层细胞表面抗原2（TROP2）的新型癌症疫苗在临床前阶段实验室测试中取得良好的早期成果，能大幅度抑制肿瘤生长。TROP2乃一种在多类癌症中有过度表现的细胞表面糖蛋白，常见于乳癌、肺癌、胰脏癌及结直肠癌。
* 长江生命科技今年迄今涨61%，同期恒生指数.HSI上扬2.8%。
* 恒生香港上市生物科技指数.HSHKBIO盘中升0.9%。（完）
更多股市简讯请点选CN-CMN-HOT
(发稿 徐凯文；审校 田镧沁)
((kaiwen.xu@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.